PhageVax, Inc. is a company specializing in developing novel vaccine technologies, particularly focusing on mucosal administration through intranasal delivery. Their T4-COVID vaccine, based on bacteriophage T4, induces strong mucosal and systemic immune responses, offering protection against various SARS-CoV-2 variants. The company's innovative platform allows for rapid vaccine production and distribution, addressing challenges in vaccine storage and distribution. PhageVax aims to combat emerging infectious diseases efficiently by providing needle-free, adjuvant-free, and stable vaccines. Their mobile vaccine solution enables quick response to pandemic threats, emphasizing the importance of timely and effective vaccine development.